Mani (7730) investor relations material

Executive summary

• Achieved record quarterly sales of ¥8.29 billion and record high net sales of ¥24,396 million for the nine months ended May 31, 2026, up 9.5% year-over-year, with operating income margin of 28.8% and profit ahead of full-year targets, driven by strong overseas sales and recovery in dental products in China.

• Operating income rose 22.0% to ¥7,486 million, and profit attributable to owners of parent increased 32.6% to ¥5,642 million year-over-year.

• Upward revision of full-year forecast reflecting robust 3Q results and stronger-than-expected sales recovery, especially in China, despite one-time expenses for factory closure.

• Growth driven by recovery in China, new product launches, strong performance in India, and accelerated R&D for next-generation products.

• Launched new medium-term management plan and accelerated R&D for next-generation products.

Financial highlights

• Net sales for 3Q YTD reached ¥24,396 million, up 9.5% year-over-year; operating income rose 22.0% to ¥7,486 million.

• Net income increased 32.6% year-over-year to ¥5,642 million; ordinary income was ¥8,036 million, up 33.3% year-over-year.

• Gross profit was ¥16,281 million (up 14.3% year-over-year) and gross margin improved due to favorable product mix and lower manufacturing costs.

• Comprehensive income reached ¥7,620 million, up 83.8% year-over-year.

• Positive FX impact contributed to revenue and profit growth.

Outlook and guidance

• Full-year forecast revised upward: net sales ¥32,900 million (+0.3%), operating income ¥9,700 million (+5.4%), ordinary income ¥10,150 million, net income ¥6,800 million (+5.4%), and EPS forecast ¥69.03.

• Includes one-time expenses related to Takanezawa Factory closure in 4Q.

• Continued focus on expanding product lineup, strengthening competitiveness in China and India, and reflecting strong sales momentum and favorable currency trends.